New TB drug development @ CSIR-National Chemical Laboratory

dc.date.accessioned	2018-06-05T13:10:07Z
dc.date.available	2018-06-05T13:10:07Z
dc.date.issued	2018-05-04
dc.identifier.uri	http://dspace.ncl.res.in:8080/xmlui/handle/20.500.12252/3936
dc.description	The Pune-based CSIR National Chemical Laboratory (CSIR-NCL), has come up with an anti-tuberculosis (anti-TB) cocrystal drug with improved stability. The research work done by professor AK Nangia and his team at the CSIR-NCL and the School of Chemistry, University of Hyderabad, has cleared the way for development of a stable formulation of 4-FDC (4 drugs fixed dose combination) for curing TB.	en_US
dc.language.iso	en	en_US
dc.publisher	Pune Mirror	en_US
dc.subject	TB drug	en_US
dc.subject	Crystal Engineering	en_US
dc.subject	Cocrystal Drug	en_US
dc.subject	Isoniazid	en_US
dc.subject	Rifampicin	en_US
dc.title	New TB drug development @ CSIR-National Chemical Laboratory	en_US
dc.type	Newspaper Article	en_US
local.division.division	Organic Chemistry Division	en_US